Stockscreener 앱 받기
3.38
2.31%
-0.08
시간 외 거래:
3.44
0.06
+1.78%
전일 마감가:
$3.46
열려 있는:
$3.64
하루 거래량:
302.70K
Relative Volume:
0.76
시가총액:
$289.26M
수익:
$351.37M
순이익/손실:
$-174.01M
주가수익비율:
-1.6329
EPS:
-2.07
순현금흐름:
$-126.94M
1주 성능:
-2.59%
1개월 성능:
-7.52%
6개월 성능:
+13.42%
1년 성능:
-3.43%
1일 변동 폭
$3.36
$3.64
1주일 범위
$3.36
$3.655
52주 변동 폭
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
명칭
Atea Pharmaceuticals Inc
전화
857-204-8109
주소
225 FRANKLIN STREET, BOSTON
AVIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.38 | 298.67M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-10-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 개시 | Evercore ISI | Outperform |
| 2020-11-24 | 개시 | JP Morgan | Overweight |
| 2020-11-24 | 개시 | Morgan Stanley | Overweight |
| 2020-11-24 | 개시 | William Blair | Outperform |
모두보기
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionMinimal Risk Growth Investment Opportunity Analysis - Newser
Atea Pharmaceuticals Inc. stock outlook for YEARStock Market Watch with Smart Filters - Newser
Visualizing Atea Pharmaceuticals Inc. stock with heatmapsBreakout Watcher with Entry and Exit Alerts - Newser
Will Atea Pharmaceuticals Inc. price bounce be sustainableSmart Swing Picks with Confirmed Signals - Newser
Atea Pharmaceuticals Inc. stock daily chart insightsAI Entry Timing Prediction for Swing Traders - Newser
Does Atea Pharmaceuticals Inc. fit your quant trading modelPattern Breakout Prediction for Short Term - Newser
Is Atea Pharmaceuticals Inc. forming a bottoming baseAI Trading Forecast Based on Big Data - Newser
Atea Pharmaceuticals (AVIR): A High-Growth HCV Play with Clinical and Financial Momentum - AInvest
Using data tools to time your Atea Pharmaceuticals Inc. exitEntry Timing Tracker with Alert Accuracy - Newser
Is Atea Pharmaceuticals Inc. meeting your algorithmic filter criteriaReal Time Alert System for Market Moves - Newser
How to build a custom watchlist for Atea Pharmaceuticals Inc.Free Weekly Potential Breakout Stock List - Newser
Signal strength of Atea Pharmaceuticals Inc. stock in tech scannersFree Trade Scanner With Buy Zone Alerts - Newser
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by Wall Street Zen - Defense World
When is the best time to exit Atea Pharmaceuticals Inc.Momentum-Based Prediction for Quick Returns - Newser
Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway - Investing.com Australia
Atea (AVIR) Q2 Loss Narrows 8% - AOL.com
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Custom watchlist performance reports with Atea Pharmaceuticals Inc.Buy and Exit Strategy Based on Momentum - Newser
Atea Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Atea Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEarnings Based Stock Performance Forecast - Newser
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
What makes Atea Pharmaceuticals Inc. stock price move sharplyTrade Flow Monitor with Volume Tracker - Newser
Atea Pharmaceuticals (AVIR) Expected to Announce Earnings on Thursday - Defense World
Is Atea Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Swing Trade Watchlist with Entry Zones - Newser
Published on: 2025-08-05 21:33:14 - Newser
Atea Pharmaceuticals Inc. stock volume spike explainedSwing Trade Signal and Price Prediction - Newser
Atea Pharmaceuticals Inc. stock trendline breakdownOversold Reversal Picks with Buy Zone - Newser
What is Atea Pharmaceuticals Inc. company’s growth strategyTriple-digit returns - Jammu Links News
Is Atea Pharmaceuticals Inc. a growth stock or a value stockBuild your wealth with consistent stock growth - Jammu Links News
What catalysts could drive Atea Pharmaceuticals Inc. stock higher in 2025Discover hidden gems in the stock market - Jammu Links News
What are the latest earnings results for Atea Pharmaceuticals Inc.Achieve rapid portfolio growth with expert help - Jammu Links News
Atea Pharmaceuticals Inc (AVIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):